These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 725844)

  • 1. Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study.
    Lowe GD; Morrice JJ; Fulton A; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1978 Aug; 40(1):134-43. PubMed ID: 725844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic defibrinogenation by ancrod: effect on limb blood flow in peripheral vascular disease.
    Wiles PG; Nelson SR; Hampton KK; Casali B; Boothby M; Prentice CR
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):385-8. PubMed ID: 2133215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous ancrod in prevention of deep-vein thrombosis after operation for fractured neck of femur.
    Lowe GD; Campbell AF; Meek DR; Forbes CD; Prentice CR
    Lancet; 1978 Sep; 2(8092 Pt 1):698-700. PubMed ID: 80632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Clinical pharmacology and rheology.
    Forbes CD; Barbenell J; Prentice CR
    Haemostasis; 1976; 5(6):348-54. PubMed ID: 1017726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous ancrod therapy in peripheral arterial disease: improvement in blood viscosity and nutritional blood flow.
    Lowe GD; Morrice JJ; Forbes CD; Prentice CR; Fulton AJ; Barbenel JC
    Angiology; 1979 Sep; 30(9):594-9. PubMed ID: 484913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man.
    Bell WR; Shapiro SS; Martinez J; Nossel HL
    J Lab Clin Med; 1978 Apr; 91(4):592-604. PubMed ID: 641385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of Arvin and surgery on red cell filterability.
    Ernst E; Dormandy J
    Scand J Clin Lab Invest Suppl; 1981; 156():317-9. PubMed ID: 6948396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of treatment with ancrod (Arwin) in 21 patients with chronic arterial occlusive disease].
    Rosendo A; Sala Planell E; Latorre J; Marinello J; Olba L; Rutllant ML
    Rev Clin Esp; 1982 Mar; 164(5):313-6. PubMed ID: 7100546
    [No Abstract]   [Full Text] [Related]  

  • 10. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiplatelet activity of ancrod on administration to rabbits.
    Chang MC; Huang TF
    J Lab Clin Med; 1995 Apr; 125(4):508-16. PubMed ID: 7706907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
    Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE
    J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dosage ancrod for prevention of thrombotic complications after surgery for fractured neck of femur.
    Barrie WW; Wood EH; Crumlish P; Forbes CD; Prentice CR
    Br Med J; 1974 Oct; 4(5937):130-3. PubMed ID: 4607845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity.
    Dempfle CE; Argiriou S; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
    Ann N Y Acad Sci; 2001; 936():210-4. PubMed ID: 11460476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheological and clotting changes in the immediate post-myocardial infarction period.
    Patrassi GM; Brunetti A; de Zio A; Gribaldo A; Cafiero F; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(1):140-9. PubMed ID: 6164609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
    Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
    Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K; Hornberger W; Kirchengast M
    Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma.
    Cole CW; Shea B; Bormanis J
    Can J Surg; 1995 Jun; 38(3):249-54. PubMed ID: 7788603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantitative evaluation of anticoagulants in experimental nephrotoxic nephritis.
    Thomson NM; Simpson IJ; Peters DK
    Clin Exp Immunol; 1975 Feb; 19(2):301-8. PubMed ID: 1212801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fibrinolytic and defibrinogenation therapy].
    Mannucci PM; Mari D
    Ric Clin Lab; 1983; 13 Suppl 3():245-55. PubMed ID: 6672998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.